TUMOR-INFILTRATING LYMPHOCYTE THERAPY
TIL THERAPY
TIL therapy is an advanced cancer immunotherapy treatment using tumor-infiltrating lymphocytes to target solid tumors, improve response rates, and expand personalized treatment options globally.
analyticsAt a Glance
- check_circleExtracts tumour-infiltrating lymphocytes, expands them, and reinfuses
- check_circleFDA approved (Lifileucel) for advanced melanoma after prior therapy
- check_circleActive programmes in China for cervical cancer, melanoma, and lung cancer
- check_circleDoes not require genetic engineering โ uses naturally reactive T-cells
What is TIL Therapy?
TIL therapy extracts T-lymphocytes that have naturally infiltrated a patient's tumor, expands them from thousands to billions in a specialized lab, and reinfuses them after chemotherapy clears immune-suppressive cells. Unlike CAR-T, no genetic engineering is used โ the cells retain their natural, multi-target diversity.
โTIL therapy is, in a sense, the original personalized cancer immunotherapy, rescuing and amplifying cells your own immune system already sent to fight.โ
It's helpful to visualize the main idea in your mind before you start learning about the science. Once you have that picture, everything else will become clear.
Cancer does not make your immune system weak. Your body sends immune cells, especially T-lymphocytes, or T-cells, into the tumor tissue even as it grows to try to fight it. Scientists can see these cells in tumor tissue under a microscope.
That's why they are called "tumor-infiltrating lymphocytes," which means they have physically entered the tumor. Their presence means your immune system sees cancer as a threat. The issue is that the tumor environment is excellent at getting rid of these cells. It stops them, tires them out, and basically takes away their weapons before they can do too much damage.
Consider it from this perspective. Picture a city that is under siege. A small group of soldiers with few supplies is trying to hold the walls against an enemy that is much bigger and better equipped.
The soldiers know who the enemy is and can tell them apart, but they are outnumbered, short on supplies, and being poisoned by the enemy's chemical weapons. They aren't failing due to ignorance; they're failing because the conditions make it difficult to fight well.
TIL therapy solves this problem by taking those soldiers out of the impossible situation, bringing them to a safe place (the lab), feeding them, training them, and turning a few thousand into ten billion. Then it gets the battlefield ready by temporarily lowering the enemy's defenses with lymphodepleting chemotherapy. After that, it sends the now-huge, re-energized army back in. In some cancers, the results have been wonderful.
Natural Multi-Target Recognition
TILs carry diverse T-cell receptors that recognize multiple tumor neoantigens simultaneously, making it harder for cancer to escape detection through antigen loss.
Autologous & Personalized
Every TIL product is made from the patient's own tumor tissue, ensuring the cells are already trained to recognize that specific cancer's targets.
Four Decades of Development
Pioneered by Dr. Steven Rosenberg at the NCI in the late 1980s, TIL therapy reached its first FDA approval in February 2024 โ decades of refinement behind a single infusion.
FDA Approved: Lifileucel (Amtagvi)
Iovance Biotherapeutics' lifileucel is approved for adults with unresectable or metastatic melanoma who progressed after a PD-1 inhibitor and, if BRAF V600E/K mutant, a BRAF inhibitor.
History Of TIL Therapy
TIL therapy is not new; it has been in development for a long time, which is important to know if you want to understand where it is now and where it is going.
The story starts at the National Cancer Institute (NCI) in Bethesda, Maryland, where Dr. Steven Rosenberg and his team showed for the first time in the late 1980s that they could take tumor-infiltrating lymphocytes out of the body, grow them outside of the body, and then put them back into the body to make tumors shrink in people with metastatic melanoma.
These initial findings were remarkable; certain patients with extensively disseminated melanoma, deemed terminal, attained complete responses. But the technology for making TILs reliably on a large scale, the knowledge of how to use lymphodepletion to get the patient ready, and the general infrastructure for adoptive cell therapy were all still in their early stages.
During the 1990s and 2000s, Rosenberg's group and collaborators at a few academic centers, including the Moffitt Cancer Center in Tampa, worked on improving the manufacturing process, optimizing the lymphodepletion regimen, and gathering enough clinical data to show that TIL therapy could produce response rates in advanced melanoma that were truly remarkable for the time. But commercial development kept getting stuck because it was thought to be too challenging and too expensive to make personalized cell therapies on a large scale.
The arrival of CAR-T cell therapy changed the situation. It indicated that the FDA could approve a personalized, manufactured cell therapy and that payers would pay for it, even if it cost a lot. It provided guidance for both businesses and regulations. It also brought in biotechnology money for the larger field of adoptive cell therapy, which includes TIL therapy. Iovance Biotherapeutics became the top commercial developer.
In February 2024, the FDA approved their TIL product, lifileucel, sold as Amtagvi, for adult patients with unresectable or metastatic melanoma who had already been treated with a PD-1 or PD-L1 checkpoint inhibitor and, if they had a BRAF V600E/K mutation, a BRAF inhibitor. This was a historic moment: the first TIL therapy that the FDA approved, proving that scientists had been working on it for almost 40 years.
TIL Therapy Success Rates
- 31.4%ORR in C-144-01 (FDA Approval Trial)Achieved in heavily pre-treated melanoma; median 3 prior therapies.
- 40โ55%ORR in NCI & Moffitt Research ProtocolsPooled historic data; includes 10โ25% complete response rates.
- 22โ34 daysManufacturing Timeline (lifileucel)Significantly shorter than early research protocols of 6โ8 weeks.
- 14โ21 daysInpatient Treatment AdmissionIncludes lymphodepleting chemo, TIL infusion, and high-dose IL-2 support.
- 80.3%Disease Control Rate in C-144-01Beyond formal tumor shrinkage, many additional patients achieved stable disease, showing broader clinical benefit in heavily pre-treated melanoma.
- 1.5 monthsMedian Time to Initial ResponseResponses to lifileucel often appeared quickly after infusion, which is a useful practical benchmark for patient-facing content.
How does TIL therapy work?
Each step has a precise biological rationale. Understanding the sequence demystifies what feels like a complex treatment.
- 1
Tumor Biopsy or Resection
A piece of the patient's tumor is surgically removed or biopsied. This tissue contains TILs that have already seen the cancer โ it is the raw manufacturing material.
- 2
TIL Isolation
The tumor tissue is processed mechanically and enzymatically at a GMP facility to separate TILs from tumor cells and stroma. Numbers at this stage: thousands to low millions.
- 3
Initial Expansion (Pre-REP)
Isolated TILs are cultured with IL-2 and OKT3 antibody for 10โ14 days. Cell count increases substantially and tumor-reactive T-cells are preferentially activated.
- 4
Rapid Expansion Protocol (REP)
Pre-expanded TILs undergo intense expansion using irradiated feeder cells, OKT3, and high-dose IL-2. Cell count is scaled to 20โ150 billion โ a 1,000ร to 2,000ร increase.
- 5
Quality Testing & Release
Strict QC testing for sterility, T-lymphocyte identity, viability (>70% required), and absence of residual tumor cells before the product is cleared for infusion.
- 6
Lymphodepleting Chemotherapy
Cyclophosphamide and fludarabine are administered for ~7 days. This eliminates suppressor immune cells, creates a pro-inflammatory vacuum, and primes the body to accept TILs.
- 7
TIL Infusion
Billions of expanded TILs are returned to the patient via IV โ a straightforward infusion lasting a few hours. The culmination of weeks of preparation.
- 8
High-Dose IL-2 Support
Up to 5 doses of high-dose IV interleukin-2 every 8 hours post-infusion support TIL survival and expansion in vivo. Requires ICU-level monitoring for capillary leak syndrome โ fully reversible.
- 9
Recovery & Response Assessment
After 1โ3 weeks of inpatient care, patients recover and undergo imaging at 6โ8 weeks. Responses can deepen over months โ a hallmark of immune-mediated therapy.
TIL Therapy vs CAR-T Cell Therapy
Both are adoptive cell therapies, but their mechanisms, strengths, and best-fit cancers differ significantly.
| Feature | TIL Therapy | CAR-T Therapy |
|---|---|---|
| Genetic Engineering | None โ cells expanded but unmodified | Synthetic CAR receptor inserted |
| Target Specificity | Multi-target (diverse TCR repertoire) | Single antigen (e.g., CD19, BCMA) |
| Best Cancer Type | Solid tumors (melanoma, cervical, NSCLC) | Blood cancers (B-ALL, DLBCL, MM) |
| Antigen Escape Risk | Lower โ attacks multiple antigens | Higher โ single-target escape possible |
| Manufacturing Time | 22โ34 days (lifileucel) | 2โ4 weeks (varies by product) |
| CRS Severity | Typically mild-moderate | Can be severe (Grade 3โ4) |
| Primary Toxicity | High-dose IL-2 (capillary leak syndrome) | CRS + ICANS (neurotoxicity) |
| FDA Approvals | Melanoma (lifileucel, 2024) | 6+ products across B-ALL, DLBCL, MM, MCL |
Clinical Efficacy Data
Decades of trial data underpin TIL therapy's FDA approval and expanding indication pipeline.
Melanoma โ C-144-01 Phase II (lifileucel)
Patients had median 3 prior therapies, all with prior anti-PD-1. Median DOR not reached at data cutoff.
Melanoma โ NCI & Moffitt Historic Protocols
Pooled analysis of decades of investigator-initiated trials in advanced melanoma.
Cervical Cancer โ MD Anderson Phase II (Nature Medicine 2022)
HPV-associated cervical cancer; Iovance IOV-COM-202 trial ongoing.
Which Cancers Can TIL Therapy Treat?
TIL therapy works best in tumors with high immune infiltration and mutational burden. Melanoma is the only FDA-approved indication; clinical trials are active across several other solid tumors.
Melanoma
The most mature application โ FDA-approved. Response rates of 30โ55% in advanced, post-immunotherapy patients, with documented multi-year durable responses.
Cervical Cancer
HPV-associated tumors present clear viral neoantigens. 44% ORR in Phase II data; Iovance IOV-COM-202 trial ongoing, FDA submission anticipated.
Non-Small Cell Lung Cancer (NSCLC)
Early studies show activity in checkpoint-refractory NSCLC. High tumor mutational burden cases appear to respond best. Multiple trials enrolling.
Head & Neck Cancer
High TIL infiltration in HPV-associated HNSCC makes it a strong candidate. Phase I/II trials are evaluating safety and efficacy.
Ovarian Cancer
Immune-rich tumor microenvironment is promising. Active trials are addressing the immunosuppressive ascites environment that limits early results.
Colorectal Cancer (MSI-H)
Microsatellite instability-high colorectal cancers have high neoantigen load, making them the most likely colorectal subtype to respond to TIL therapy.
Who Is (and Is Not) a Candidate for TIL Therapy
Eligibility depends on performance status, tumor accessibility, and prior treatment history. Assess early โ eligibility can worsen as disease progresses.
Likely Eligible
- Advanced or metastatic solid tumorMelanoma (FDA-approved); cervical, NSCLC, HNSCC via trials.
- Progression after standard therapyPrior PD-1 inhibitor required for lifileucel; prior chemo/targeted therapy.
- Adequate organ functionNormal kidney, liver, heart, and lung function to tolerate lymphodepletion and IL-2.
- Resectable or biopsyable tumor lesionSufficient tissue must be accessible to manufacture the TIL product.
- Performance status ECOG 0โ1Fit enough for intensive inpatient treatment over 2โ3 weeks.
Typically Not Eligible
- Rapidly progressing diseaseCannot safely wait 3โ5 weeks for manufacturing without disease control.
- Severe organ dysfunctionCompromised kidney, liver, cardiac, or pulmonary function precludes safe IL-2.
- Active autoimmune diseaseRequires immunosuppression incompatible with TIL engraftment.
- Active CNS metastasesUntreated or unstable brain metastases are generally exclusionary.
- No biopsiable tumorManufacturing is impossible without obtainable tumor tissue.
Side Effects: What to Expect
TIL therapy has a distinct toxicity profile driven by its three components: lymphodepleting chemotherapy, TIL infusion, and high-dose IL-2. Experienced centers manage these predictably.
Lymphodepletion (Chemo Phase)
Cyclophosphamide and fludarabine cause nausea, fatigue, hair thinning, and transient neutropenia. Prophylactic antibiotics and antifungals are standard. Blood counts recover within 1โ2 weeks.
TIL Infusion Reactions
Short-term fever, chills, and flu-like symptoms are common in the hours post-infusion. CRS can occur but is typically less severe than with CAR-T therapy.
High-Dose IL-2 Toxicity
The most significant toxicity: capillary leak syndrome causing fluid redistribution, hypotension, and edema. Requires ICU-level monitoring. Fully reversible within days of stopping IL-2.
Overall Safety Profile
For patients with limited options, TIL therapy's toxicity is considered acceptable versus salvage chemotherapy. No ICANS (neurotoxicity) unlike CAR-T. Long-term immune-related effects are rare.
Cost of TIL therapy
The cost of TIL therapy presents a significant barrier for many patients. In the USA, a single treatment like Amtagvi can exceed $515,000. Conversely, TIL therapy in China is considerably more affordable, ranging from $50,000 to $125,000. Clinical trials offer an alternative pathway to access this innovative treatment, often at reduced or no cost, and are crucial for advancing TIL therapy research globally.
| Region | Cost |
|---|---|
| United States | $350,000 to $500,000 |
| Europe | $200,000 to $350,000 |
| China | $80,000 to $200,000 |
How to Access TIL Therapy: 4 Pathways
Access flows through three distinct routes depending on diagnosis, geography, and trial availability.
- 1
Pathway 1: Commercial Lifileucel (Melanoma)
Lifileucel (Amtagvi) is FDA-approved and available through Iovance's Authorized Treatment Center (ATC) network for eligible melanoma patients. Your oncologist prescribes it; Iovance manages manufacturing logistics.
- 2
TIL Therapy in China
China is one of the most active global centers for TIL therapy research and clinical application, with leading hospitals exploring it for melanoma, cervical cancer, lung cancer, and other solid tumors. It offers patients access to advanced protocols, experienced cell-therapy teams, and often more cost-effective treatment pathways.
- 3
Pathway 2: Clinical Trials
For non-melanoma solid tumors or patients not meeting commercial criteria, clinical trials are the primary route. Iovance, NCI, Moffitt, MD Anderson, and international academic centers are actively enrolling. CancerFax monitors open TIL trials globally and matches patients to appropriate studies.
- 4
Pathway 3: International TIL Centers
The Karolinska Institutet (Stockholm), Netherlands Cancer Institute (Amsterdam), and select centers in Singapore and South Korea offer TIL programs. CancerFax has facilitated international TIL access for patients from India, the Middle East, and Southeast Asia.
Explore Further Details on TIL Therapy
Dive deeper into TIL therapy topics and related cell therapy options.
- What is TIL Therapy?
- How TIL Therapy Works
- TIL vs CAR-T Therapy
- TIL vs Immunotherapy
- Cancers Treated with TIL Therapy
- TIL Therapy for Melanoma
- TIL Therapy for Lung Cancer
- TIL Therapy for Cervical Cancer
- Eligibility for TIL Therapy
- TIL Treatment Process
- Tumor Tissue Collection
- TIL Cell Expansion in Laboratory
- Lymphodepletion Before TIL Therapy
- Side Effects of TIL Therapy
- Success Rates of TIL Therapy
- Cost of TIL Therapy
- Clinical Trials in TIL Therapy
- FDA Approval of TIL Therapy
- Future of TIL Research
- Questions to Ask Before TIL Treatment
Frequently Asked Questions on TIL Therapy
Answers to the questions patients and caregivers ask most about TIL therapy.
Basics
What is TIL therapy?
TIL therapy, or tumor-infiltrating lymphocyte therapy, is a type of adoptive cell therapy that uses a patient's own immune cells to fight cancer. Doctors remove a small piece of the tumor, isolate the immune cells already inside it (the tumor-infiltrating lymphocytes), grow them into very large numbers in a specialized lab, and then return them to the patient through an infusion. The idea is simple at its core: these cells have already recognized the tumor, so multiplying and reinforcing them gives the immune system a much stronger attack.
How is TIL therapy different from CAR-T therapy?
Both are forms of cell therapy that use a patient's own immune cells, but they work differently. CAR-T therapy genetically engineers T-cells to target one specific marker on cancer cells, which works well in certain blood cancers. TIL therapy does not genetically modify the cells. Instead, it expands the natural immune cells found within the solid tumor, which often recognize several different targets at once. This is one reason TIL therapy has been studied mainly in solid tumors such as melanoma, where CAR-T has been less effective.
Efficacy & Outcomes
How effective is TIL therapy?
Results vary by cancer type, disease stage, and how heavily the patient has been treated before. In advanced melanoma that has progressed after other treatments, clinical studies have shown meaningful and sometimes durable responses in a portion of patients, which led to the first regulatory approval of a TIL product for melanoma. It is important to be realistic here. TIL therapy does not work for everyone, and response rates are not the same as cure rates. Eligibility and likely benefit can only be judged after a full review of the diagnosis, pathology, prior treatment history, and overall health.
Can TIL therapy cure cancer?
TIL therapy can produce long-lasting responses in some patients, and a smaller number experience extended periods with no detectable disease. But it should not be described as a guaranteed cure. For most patients it is best understood as a powerful option that may control advanced disease when standard treatments have stopped working, rather than a certainty. The honest answer for any individual depends on expert evaluation, and outcomes cannot be promised in advance.
Treatment Process
What does the TIL treatment process involve?
The process usually moves through a few clear stages. First, a portion of the tumor is surgically removed so the immune cells can be harvested. Those cells are then grown in a specialized laboratory over several weeks. Before the expanded cells are infused back, the patient typically receives a short course of chemotherapy to prepare the body to accept them. After the infusion, patients usually receive a medicine called interleukin-2 to help the new cells survive and stay active. Because of this sequence, the full journey often takes several weeks and requires close hospital supervision.
What are the side effects of TIL therapy?
The side effects mostly come from the chemotherapy given before the infusion and the interleukin-2 given afterward, rather than from the immune cells themselves. These can include a temporary drop in blood counts, increased infection risk, fever, fluid retention, low blood pressure, and fatigue. Most of these effects are managed in a hospital setting and tend to improve with time and supportive care. The exact risk profile differs from patient to patient, which is why TIL therapy is only carried out in experienced centers with proper monitoring.
Access & Availability
Is TIL therapy available in India?
At present, TIL therapy is not widely available as a standard treatment in India and is mainly accessible through specialized international centers and clinical trials, including programs in China and other advanced oncology hospitals. Availability is changing as more centers develop cell therapy capabilities, so the practical options for any patient depend on their cancer type, current disease status, and whether they are willing to consider treatment abroad. A case review is usually needed to understand which centers and pathways are realistic.
How can CancerFax help patients access TIL therapy?
CancerFax helps patients and families explore whether TIL therapy is a suitable option and, where appropriate, connects them with advanced cancer centers and clinical trials that offer it. This support can include reviewing medical records, arranging expert second opinions, checking molecular and pathology reports, and coordinating the practical aspects of international care, such as hospital communication, documentation, translation, and travel. The first step is always a careful review of the patient's case, because TIL therapy is only appropriate after proper medical evaluation confirms it may help.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Could TIL Therapy Be Right for You?
CancerFax has helped patients from India, the Middle East, and Southeast Asia access TIL therapy trials and international treatment centers. Upload your reports for a no-obligation case review by our oncology team.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.